Jack Ansell

32.9k total citations · 9 hit papers
225 papers, 16.4k citations indexed

About

Jack Ansell is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Surgery. According to data from OpenAlex, Jack Ansell has authored 225 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Cardiology and Cardiovascular Medicine, 120 papers in Internal Medicine and 30 papers in Surgery. Recurrent topics in Jack Ansell's work include Atrial Fibrillation Management and Outcomes (165 papers), Venous Thromboembolism Diagnosis and Management (120 papers) and Cardiac Arrhythmias and Treatments (47 papers). Jack Ansell is often cited by papers focused on Atrial Fibrillation Management and Outcomes (165 papers), Venous Thromboembolism Diagnosis and Management (120 papers) and Cardiac Arrhythmias and Treatments (47 papers). Jack Ansell collaborates with scholars based in United States, Canada and United Kingdom. Jack Ansell's co-authors include Jack Hirsh, Elaine M. Hylek, Alan K. Jacobson, L. Poller, Henry I. Bussey, Mark Crowther, Daniel Deykin, Gualtiero Palareti, James E. Dalen and Jonathan L. Halperin and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Jack Ansell

219 papers receiving 15.6k citations

Hit Papers

Pharmacology and Management of the Vitamin K Antagonists 2001 2026 2009 2017 2008 2001 2004 2003 2008 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pharmacology and Management of the Vitamin K Antagonists
    2008 1.6k citations Jack Ansell, Jack Hirsh et al. profile →
  2. Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
    2001 1.2k citations Jack Ansell et al. profile →
  3. The Pharmacology and Management of the Vitamin K Antagonists
    2004 1.1k citations Jack Ansell, Jack Hirsh et al. profile →
  4. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
    2003 645 citations Jack Hirsh, Valentı́n Fuster et al. Circulation profile →
  5. The Perioperative Management of Antithrombotic Therapy
    2008 554 citations Jack Ansell et al. profile →
  6. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes
    2016 353 citations Benjamin A. Steinberg, Peter Shrader et al. Journal of the American College of Cardiology profile →
  7. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
    2018 329 citations Daniel M. Witt, Robby Nieuwlaat et al. Blood Advances profile →
  8. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
    2015 314 citations Emily C. O’Brien, Laine Thomas et al. European Heart Journal profile →
  9. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
    2019 214 citations Mark Crowther, Jack Ansell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jack Ansell United States 62 11.7k 7.5k 2.5k 1.7k 1.5k 225 16.4k
Paul Reilly United States 42 15.7k 1.3× 7.8k 1.0× 1.2k 0.5× 2.4k 1.4× 692 0.4× 128 17.5k
Elaine M. Hylek United States 79 24.3k 2.1× 11.1k 1.5× 2.7k 1.1× 4.6k 2.7× 1.4k 0.9× 252 31.2k
Jonas Oldgren Sweden 48 19.5k 1.7× 8.3k 1.1× 1.7k 0.7× 2.8k 1.6× 633 0.4× 196 21.5k
Scott D. Berkowitz United States 54 13.6k 1.2× 8.8k 1.2× 3.3k 1.4× 1.9k 1.1× 2.0k 1.3× 195 17.0k
Brian F. Gage United States 55 9.7k 0.8× 3.5k 0.5× 1.9k 0.8× 2.2k 1.3× 593 0.4× 180 17.4k
James E. Dalen United States 63 11.9k 1.0× 6.6k 0.9× 5.3k 2.1× 2.1k 1.2× 1.5k 1.0× 204 18.4k
Vittorio Pengo Italy 63 6.6k 0.6× 5.8k 0.8× 2.4k 1.0× 1.0k 0.6× 5.6k 3.6× 367 16.3k
Janice Pogue Canada 42 14.7k 1.3× 4.7k 0.6× 2.0k 0.8× 2.9k 1.7× 421 0.3× 74 19.3k
Philip S. Wells Canada 63 10.4k 0.9× 14.9k 2.0× 5.6k 2.3× 2.0k 1.1× 3.2k 2.1× 299 19.7k
Rafael Díaz Argentina 45 12.7k 1.1× 4.1k 0.5× 3.1k 1.2× 1.9k 1.1× 745 0.5× 130 18.4k

Countries citing papers authored by Jack Ansell

Since Specialization
Citations

This map shows the geographic impact of Jack Ansell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Ansell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Ansell more than expected).

Fields of papers citing papers by Jack Ansell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jack Ansell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Ansell. The network helps show where Jack Ansell may publish in the future.

Co-authorship network of co-authors of Jack Ansell

This figure shows the co-authorship network connecting the top 25 collaborators of Jack Ansell. A scholar is included among the top collaborators of Jack Ansell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jack Ansell. Jack Ansell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Witt, Daniel M., Robby Nieuwlaat, Nathan P. Clark, et al.. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Advances. 2(22). 3257–3291. 329 indexed citations breakdown →
2.
Laulicht, Bryan, Sasha Bakhru, Solomon S. Steiner, & Jack Ansell. (2018). Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time. Blood. 132(Supplement 1). 987–987. 3 indexed citations
3.
4.
Ansell, Jack. (2016). Reversal Agents for the Direct Oral Anticoagulants. Hematology/Oncology Clinics of North America. 30(5). 1085–1098. 5 indexed citations
5.
Diener, Hans‐Christoph, James Aisenberg, Jack Ansell, et al.. (2016). Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. European Heart Journal. 38(12). ehv643–ehv643. 110 indexed citations
6.
Barnes, Geoffrey D., Walter Ageno, Jack Ansell, & Scott Kaatz. (2015). Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 13(6). 1154–1156. 101 indexed citations
7.
Steinberg, Benjamin A., Eric D. Peterson, Sunghee Kim, et al.. (2014). Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Circulation. 131(5). 488–494. 149 indexed citations
8.
Küpfer, K., et al.. (2014). STABLE results: warfarin home monitoring achieves excellent INR control.. PubMed. 20(3). 202–9. 27 indexed citations
9.
Held, Claes, Elaine M. Hylek, John H. Alexander, et al.. (2014). Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. European Heart Journal. 36(20). 1264–1272. 124 indexed citations
10.
Granger, Christopher B., Renato D. Lópes, Michael G. Hanna, et al.. (2014). Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal. 169(1). 25–30. 49 indexed citations
11.
Piccini, Jonathan P., DaJuanicia N. Holmes, Elizabeth Fraulo, et al.. (2011). Abstract 16415: Patterns of Atrial Fibrillation and Treatment Strategies Vary According to Provider Specialty Across Community Practice Settings: Findings From the ORBIT-AF Registry. Circulation. 124. 53–5. 2 indexed citations
12.
Piccini, Jonathan P., DaJuanicia N. Holmes, Winnie W. Nelson, et al.. (2011). Abstract 15347: Symptom Status and Treatment Strategy in Contemporary Management of Atrial Fibrillation: Findings From the ORBIT-AF Registry. Circulation. 124.
13.
Ansell, Jack, et al.. (2007). Descriptive Analysis of the Process and Quality of Oral Anticoagulation Management in Real-Life Practice in Patients with Chronic Non-valvular Atrial Fibrillation. UCL Discovery (University College London). 2 indexed citations
14.
Ansell, Jack. (2005). Effects of dietary supplements on hemostasis. Thrombosis Research. 117(1-2). 45–47.
15.
Nutescu, Edith A., et al.. (2004). Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Clinics. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 24(9). 1204–1212. 4 indexed citations
16.
Hirsh, Jack, Valentı́n Fuster, Jack Ansell, & Jonathan L. Halperin. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.. Journal of the American College of Cardiology. 41(9). 1633–1652. 229 indexed citations
17.
Schmitt, Laurenz, Jeanne L. Speckman, & Jack Ansell. (2003). Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range. Journal of Thrombosis and Thrombolysis. 15(3). 213–216. 156 indexed citations
18.
Stone, Sarah, et al.. (1989). Comparison between videotape and personalized patient education for anticoagulant therapy.. PubMed. 29(1). 55–7. 37 indexed citations
19.
Sullivan, J L, et al.. (1987). Virus-associated hemophagocytic syndrome: Identification of an immunoproliferative precursor lesion. Human Pathology. 18(10). 1071–1074. 11 indexed citations
20.
Ansell, Jack, et al.. (1982). On the small sample estimation of the log odds ratio in 2×2 contingency tables with one set of fixed margins. Journal of Statistical Computation and Simulation. 14(3-4). 305–320.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Reilly Breakdown of academic impact, for papers by Elaine M. Hylek Breakdown of academic impact, for papers by Jonas Oldgren Breakdown of academic impact, for papers by Scott D. Berkowitz Breakdown of academic impact, for papers by Brian F. Gage Breakdown of academic impact, for papers by James E. Dalen Breakdown of academic impact, for papers by Vittorio Pengo Breakdown of academic impact, for papers by Janice Pogue Breakdown of academic impact, for papers by Philip S. Wells Breakdown of academic impact, for papers by Rafael Díaz
Rankless by CCL
2026